Related references
Note: Only part of the references are listed.Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer
Rohan Gupta et al.
ONCOLOGIST (2020)
Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers
Aparna R. Parikh et al.
CLINICAL CANCER RESEARCH (2020)
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
M. C. Liu et al.
ANNALS OF ONCOLOGY (2020)
Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study
Jeanne Tie et al.
GUT (2019)
Clinical utility of circulating tumor DNA for colorectal cancer
Hiroki Osumi et al.
CANCER SCIENCE (2019)
Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies
Gianluca Mauri et al.
CANCER TREATMENT REVIEWS (2019)
A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer
Hideaki Bando et al.
BRITISH JOURNAL OF CANCER (2019)
Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer
Yuxuan Wang et al.
JAMA ONCOLOGY (2019)
Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer
Thomas Reinert et al.
JAMA ONCOLOGY (2019)
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
Aparna R. Parikh et al.
NATURE MEDICINE (2019)
Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge
C. M. Parseghian et al.
ANNALS OF ONCOLOGY (2019)
Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer
Jeanne Tie et al.
JAMA ONCOLOGY (2019)
Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer
Hiroki Osumi et al.
CANCER MEDICINE (2019)
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan A Phase 2 Single-Arm Clinical Trial
Chiara Cremolini et al.
JAMA ONCOLOGY (2019)
Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel
Jason Willis et al.
CLINICAL CANCER RESEARCH (2019)
Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer
John H. Strickler et al.
CANCER DISCOVERY (2018)
RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study
J. B. Bachet et al.
ANNALS OF ONCOLOGY (2018)
Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer
Rona Yaeger et al.
CANCER CELL (2018)
Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival
David H. Murray et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2018)
Targeted Sequencing of Circulating Tumor DNA to Monitor Genetic Variants and Therapeutic Response in Metastatic Colorectal Cancer
Hung-Chih Hsu et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection
Christopher Abbosh et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
A. Grothey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Combined BRAF, EGFR, and MEK Inhibition in Patients with &ITBRAF&ITV600E-Mutant Colorectal Cancer
Ryan B. Corcoran et al.
CANCER DISCOVERY (2018)
Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multi-kinase inhibitor
Caroline Vandeputte et al.
Oncotarget (2018)
Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses A Phase 2 Randomized Clinical Trial
Clara Montagut et al.
JAMA ONCOLOGY (2018)
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
David R. Gandara et al.
NATURE MEDICINE (2018)
Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial
Khurum H. Khan et al.
CANCER DISCOVERY (2018)
Sensitive tumour detection and classification using plasma cell-free DNA methylomes
Shu Yi Shen et al.
NATURE (2018)
Application of Cell-free DNA Analysis to Cancer Treatment
Ryan B. Corcoran et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer
Filippo Pietrantonio et al.
CLINICAL CANCER RESEARCH (2017)
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
Christopher Abbosh et al.
NATURE (2017)
Integrating liquid biopsies into the management of cancer
Giulia Siravegna et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
Karen-Lise G. Spindler et al.
ONCOLOGIST (2017)
Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling
Aadel A. Chaudhuri et al.
CANCER DISCOVERY (2017)
Comparison of 2 Commercially Available Next-Generation Sequencing Platforms in Oncology
Nicole M. Kuderer et al.
JAMA ONCOLOGY (2017)
Clinical utility of circulating cell-free DNA in advanced colorectal cancer
Allan A. Lima Pereira et al.
PLOS ONE (2017)
Circulating tumor DNA (ctDNA) utilizing a high-sensitivity panel to detect minimal residual disease post liver hepatectomy and predict disease recurrence.
Michael J. Overman et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer
Lone V. Scholer et al.
CLINICAL CANCER RESEARCH (2017)
Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine
Hatim Husain et al.
CLINICAL CANCER RESEARCH (2017)
NSABP FC-7 correlative study: HER2 amplification (amp) in circulating cell-free DNA (cfDNA) in metastatic colorectal cancer (mCRC) resistant to anti-EGFR therapy (tx)
S. Rim Kim et al.
CANCER RESEARCH (2017)
Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients
J. Vidal et al.
ANNALS OF ONCOLOGY (2017)
Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery
Thomas Reinert et al.
GUT (2016)
Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer
Mariangela Russo et al.
CANCER DISCOVERY (2016)
Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA
G. Gremel et al.
ANNALS OF ONCOLOGY (2016)
Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance)
Donna Niedzwiecki et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations
Sabrina Arena et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
Jeanne Tie et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
Beth O. van Emburgh et al.
NATURE COMMUNICATIONS (2016)
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation
David S. Hong et al.
CANCER DISCOVERY (2016)
MET amplification in metastatic colorectal cancer: An acquired response to EGFR inhibition, not a de novo phenomenon
Kanwal Raghav et al.
ONCOTARGET (2016)
Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA
Young Kwang Chae et al.
ONCOTARGET (2016)
Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer
Adrian G. Sacher et al.
JAMA ONCOLOGY (2016)
HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer.
Kanwal Pratap Singh Raghav et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment
M. P. Morelli et al.
ANNALS OF ONCOLOGY (2015)
Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer
J. Tie et al.
ANNALS OF ONCOLOGY (2015)
Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
Sabrina Arena et al.
CLINICAL CANCER RESEARCH (2015)
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
Tony Mok et al.
CLINICAL CANCER RESEARCH (2015)
FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer
C. Bokemeyer et al.
EUROPEAN JOURNAL OF CANCER (2015)
Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials
Funda Meric-Bernstam et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Predictors of Guideline Treatment Nonadherence and the Impact on Survival in Patients With Colorectal Cancer
Robert B. Hines et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2015)
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Giulia Siravegna et al.
NATURE MEDICINE (2015)
Subclonal diversification of primary breast cancer revealed by multiregion sequencing
Lucy R. Yates et al.
NATURE MEDICINE (2015)
Genomic Classifier ColoPrint Predicts Recurrence in Stage II Colorectal Cancer Patients More Accurately Than Clinical Factors
Scott Kopetz et al.
ONCOLOGIST (2015)
Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas
Yuxuan Wang et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer
Isaac Garcia-Murillas et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
A Two-Gene Blood Test for Methylated DNA Sensitive for Colorectal Cancer
Susanne K. Pedersen et al.
PLOS ONE (2015)
Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA
Richard B. Lanman et al.
PLOS ONE (2015)
O-0011 * FREQUENCY OF S492R MUTATIONS IN THE EPIDERMAL GROWTH FACTOR RECEPTOR: ANALYSIS OF PLASMA DNA FROM METASTATIC COLORECTAL CANCER PATIENTS TREATED WITH PANITUMUMAB OR CETUXIMAB MONOTHERAPY
K. Newhall et al.
ANNALS OF ONCOLOGY (2014)
Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle
L. De Mattos-Arruda et al.
ANNALS OF ONCOLOGY (2014)
Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin
Katherine A. Hoadley et al.
CELL (2014)
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition
Teresa Troiani et al.
CLINICAL CANCER RESEARCH (2014)
Liquid Biopsies: Genotyping Circulating Tumor DNA
Luis A. Diaz et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer
Sandra Misale et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer
Genevieve M. Boland et al.
CANCER (2013)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy
Emanuele Valtorta et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
Muhammed Murtaza et al.
NATURE (2013)
Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Jean-Yves Douillard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Alberto Bardelli et al.
CANCER DISCOVERY (2013)
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Sandra Misale et al.
NATURE (2012)
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Luis A. Diaz et al.
NATURE (2012)
Comprehensive molecular characterization of human colon and rectal cancer
Donna M. Muzny et al.
NATURE (2012)
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
Clara Montagut et al.
NATURE MEDICINE (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
High-Throughput Droplet Digital PCR System for Absolute Quantitation of DNA Copy Number
Benjamin J. Hindson et al.
ANALYTICAL CHEMISTRY (2011)
Validation Study of a Quantitative Multigene Reverse Transcriptase-Polymerase Chain Reaction Assay for Assessment of Recurrence Risk in Patients With Stage II Colon Cancer
Richard G. Gray et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A Molecularly Annotated Platform of Patient-Derived Xenografts (Xenopatients) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
Andrea Bertotti et al.
CANCER DISCOVERY (2011)
CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer
Daniel J. Weisenberger et al.
NATURE GENETICS (2006)
BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions
Frank Diehl et al.
NATURE METHODS (2006)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Share Paper
